Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

ClinicalTrials.gov ID: NCT01462292

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01462292. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Exploratory Study to Assess Two Doses of GSK2402968 in the Treatment of Ambulant Boys With Duchenne Muscular Dystrophy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study.

Study identification

NCT ID
NCT01462292
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
51 participants

Conditions and interventions

Eligibility (public fields only)

Age range
5 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 26, 2011 (Actual)
Primary completion
May 21, 2013 (Actual)
Completion
Nov 4, 2013 (Actual)
Last update posted
Oct 16, 2017

2011 – 2013

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
GSK Investigational Site Sacramento California 95817 —
GSK Investigational Site Stanford California 94305 —
GSK Investigational Site Gulf Breeze Florida 32561 —
GSK Investigational Site Iowa City Iowa 52242 —
GSK Investigational Site Kansas City Kansas 66160 —
GSK Investigational Site Baltimore Maryland 21205 —
GSK Investigational Site Minneapolis Minnesota 55455 —
GSK Investigational Site St Louis Missouri 63110 —
GSK Investigational Site New York New York 10032 —
GSK Investigational Site Durham North Carolina 27710 —
GSK Investigational Site Cincinnati Ohio 45229 —
GSK Investigational Site Columbus Ohio 43205 —
GSK Investigational Site Portland Oregon 97239 —
GSK Investigational Site Dallas Texas 75207 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01462292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 16, 2017 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.